- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07237308
BEACON-AA: Apixaban s klopidogrelem nebo bez něj u pacientů po cévní mozkové příhodě s fibrilací síní a cerebrální aterosklerózou
Multicentrická prospektivní randomizovaná studie k hodnocení účinnosti apixabanu a klopidogrelu v prevenci recidivy ischemické cévní mozkové příhody u pacientů s fibrilací síní a mozkovou aterosklerózou
This trial aims to compare the safety and efficacy of apixaban alone versus apixaban combined with clopidogrel in patients with acute ischemic stroke associated with non-valvular atrial fibrillation and concomitant symptomatic intracranial or extracranial atherosclerosis or complex plaque in the ascending aorta or aortic arch (≥4 mm in thickness, mobile, or ulcerated). Participants will be randomly assigned in a 1:1 ratio to receive apixaban monotherapy or dual therapy with clopidogrel for 30 days. The primary outcome is the incidence of new symptomatic or asymptomatic ischemic lesions on DWI/FLAIR at 30 (±5) days compared with baseline MRI, adjudicated by a central committee.
Přehled studie
Postavení
Intervence / Léčba
Detailní popis
Although oral anticoagulants are effective in preventing cardioembolic stroke in patients with non-valvular atrial fibrillation (NVAF), a considerable proportion of ischemic strokes in these patients are caused by concomitant large artery atherosclerosis. Carotid or intracranial artery stenosis is present in a substantial number of patients with NVAF and is associated with a higher risk of recurrent cerebral infarction despite standard anticoagulation. In such patients, adding an antiplatelet agent to oral anticoagulation may theoretically reduce atherothrombotic events, but it also raises concern for increased bleeding risk. Recent clinical evidence on this issue remains limited, and the optimal antithrombotic strategy for patients with NVAF and coexisting symptomatic atherosclerotic stenosis has not been clearly established.
The BEACON-AA trial is a multicenter, randomized, open-label, blinded-endpoint (PROBE) study designed to compare the safety and efficacy of apixaban monotherapy versus apixaban combined with clopidogrel in patients with acute ischemic stroke associated with non-valvular atrial fibrillation (NVAF) and concomitant symptomatic intracranial or extracranial atherosclerosis or complex plaque in the ascending aorta or aortic arch (≥4 mm in thickness, mobile, or ulcerated). Participants will be randomized in a 1:1 ratio to receive apixaban alone or apixaban plus clopidogrel for 30 days, followed by apixaban monotherapy thereafter.
Brain MRI including diffusion-weighted and FLAIR sequences will be performed at baseline and at 30 ± 5 days to assess new or recurrent ischemic lesions. The primary efficacy outcome is the incidence of new symptomatic or asymptomatic ischemic lesions on DWI/FLAIR at 30(±5) days compared with baseline MRI, adjudicated by a central committee. Secondary efficacy outcomes include: 1) incidence of symptomatic ischemic stroke or transient ischemic attack within 90 days, 2) incidence of acute coronary syndrome within 90 days,3) cardiovascular mortality within 90 days, 4) composite major cardiovascular events within 90 days, 5) all-cause mortality within 90 days, 6) proportion of patients with modified Rankin Scale (mRS) 0-2 at 90 days, and 7) proportion of patients with mRS 0-3 at 90 days. The primary safety outcomes are: 1) incidence of major bleeding within 90 days, defined according to the International Society on Thrombosis and Haemostasis (ISTH) criteria and 2) incidence of new asymptomatic cerebral hemorrhages detected on brain MRI(MR-Diffusion/FLAIR/SWI (or GRE)) at 30 ± 5 days after randomization. All imaging and clinical events will be independently adjudicated by blinded central adjudication committees.
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 4
Kontakty a umístění
Studijní kontakt
- Jméno: Young Dae Kim, M.D. Ph.D.
- Telefonní číslo: 02-2228-1619
- E-mail: NEURO05@YUHS.AC
Studijní místa
-
-
-
Busan, Jižní Korea
- Nábor
- Pusan National University Hospital
-
Kontakt:
- Han-Jin Cho, Professor
- Telefonní číslo: '+82--51-240-7000
- E-mail: chohj75@gmail.com
-
Busan, Jižní Korea
- Nábor
- Dong-A University Hospital
-
Kontakt:
- Jung Hwa Seo, Professor
- Telefonní číslo: +82-51-240-2000
- E-mail: jhseo34@gmail.com
-
Chuncheon, Jižní Korea
- Nábor
- Hallym University Chuncheon Sacred Heart Hospital
-
Kontakt:
- Chulho Kim, Professor
- Telefonní číslo: +82-33-240-5000
- E-mail: gumdol52@naver.com
-
Daegu, Jižní Korea
- Nábor
- Keimyung University Dongsan Hospital
-
Kontakt:
- Sung-Il Sohn, Professor
- Telefonní číslo: +82-1577-6622
- E-mail: sungil.sohn@gmail.com
-
Goyang, Jižní Korea
- Nábor
- National Health Insurance Service Ilsan Hospital
-
Kontakt:
- Gyu Sik Kim, Professor
- Telefonní číslo: '+82-1577-0013
- E-mail: myoungsim@naver.com
-
Incheon, Jižní Korea
- Nábor
- Inha University Hospital
-
Kontakt:
- Hee-Kwon Park, Professor
- Telefonní číslo: '+82-32-890-2114
- E-mail: parkhkwon@gmail.com
-
Incheon, Jižní Korea
- Nábor
- Gachon University Gil Medical Center
-
Kontakt:
- Sang Hee Ha, Professor
- Telefonní číslo: +82-1577-2299
- E-mail: shha31@naver.com
-
Incheon, Jižní Korea
- Nábor
- Catholic Kwandong University International St. Mary's Hospital
-
Kontakt:
- Sang-Jun Ahn, Professor
- Telefonní číslo: +82-1600-8291
- E-mail: neuroan@gmail.com
-
Seoul, Jižní Korea
- Nábor
- Samsung Medical Center
-
Kontakt:
- Woo-Keun Seo, Professor
- Telefonní číslo: '+82-2-2-3410-2114
- E-mail: mcastenosis@gmail.com
-
Seoul, Jižní Korea
- Nábor
- Seoul National University Hospital
-
Kontakt:
- Keun-Hwa Jung, Professor
- Telefonní číslo: +82-1588-5700
- E-mail: jungkh@gmail.com
-
Seoul, Jižní Korea
- Nábor
- Korea University Anam Hospital
-
Kontakt:
- Sungwook Yu, Professor
- Telefonní číslo: '+82-1577-0083
- E-mail: song4yu@korea.ac.kr
-
Seoul, Jižní Korea
- Nábor
- Kangbuk Samsung Hospital
-
Kontakt:
- Jang-Hyun Baek, Professor
- Telefonní číslo: '+82-1599-8114
- E-mail: janghyun.baek@gmail.com
-
Seoul, Jižní Korea
- Nábor
- Ewha Womans University Seoul Hospital
-
Kontakt:
- Tae-Jin Song, Professor
- Telefonní číslo: +82-1522-7000
- E-mail: knstar@hanmail.net
-
Seoul, Jižní Korea
- Nábor
- Gangnam Severance Hospital
-
Kontakt:
- Yo Han Jung, Professor
- Telefonní číslo: +82-1599-6114
- E-mail: YHJUNG@yuhs.ac
-
Seoul, Jižní Korea
- Nábor
- Hanyang University Seoul Hospital
-
Kontakt:
- Young Seo Kim, Professor
- Telefonní číslo: +82-2-2290-8114
- E-mail: aescula@hanmail.net
-
Seoul, Jižní Korea
- Nábor
- Kyung Hee University Hospital
-
Kontakt:
- Jung Hyun Park, Professor
- Telefonní číslo: +82-2-958-8114
- E-mail: truelove1@hanmail.net
-
Seoul, Jižní Korea
- Nábor
- Kyung Hee University Hospital at Gangdong
-
Kontakt:
- Il Hyung Lee, Professor
- Telefonní číslo: +82-1577-5800
- E-mail: neu210@naver.com
-
Seoul, Jižní Korea
- Nábor
- Inje University Sanggye Paik Hospital
-
Kontakt:
- Sang Won Han, Professor
- Telefonní číslo: '+82-2-950-1114
- E-mail: sah1puyo@gmail.com
-
Seoul, Jižní Korea
- Nábor
- Kangdong Sacred Heart Hospital
-
Kontakt:
- Yerim Kim, Professor
- Telefonní číslo: +821588-4100
- E-mail: brainyrk@gmail.com
-
Seoul, Jižní Korea
- Nábor
- Yonsei University College of Medicine
-
Kontakt:
- Young Dae Kim, Professor
- Telefonní číslo: +82-2-2228-1619
- E-mail: NEURO05@YUHS.AC
-
Yŏngin, Jižní Korea
- Nábor
- Yongin Severance Hospital
-
Kontakt:
- Jinkwon Kim, Professor
- Telefonní číslo: +82-1899-1004
- E-mail: ANTITHROMBUS@yuhs.ac
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
Adults aged 19 years or older at the time of enrollment.
-
Patients with non-valvular atrial fibrillation (NVAF) documented by electrocardiography.
-
Acute ischemic stroke confirmed by brain MRI (diffusion-weighted and FLAIR sequences), with last known well within 120 hours prior to randomization.
-
Presence of clinically significant atherosclerosis in the cerebral or aortic arteries, meeting at least one of the following criteria:
① ≥30% stenosis in the relevant artery (the artery supplying the infarcted territory) demonstrated by CTA, MRA, or DSA - using the WASID criteria for intracranial arteries and NASCET criteria for extracranial arteries.
② High-risk atherosclerotic plaque features in the relevant artery demonstrated by CTA, MRA, or ultrasound, such as ulceration, intraplaque hemorrhage, mobile plaque, or a large lipid core (involving ≥25% of plaque cross-sectional area) on CTA/MRA, or ulceration, mobile plaque, or hypoechoic/echolucent plaque on ultrasound; or presence of branch artery occlusive disease (BAOD).
③ Complex aortic plaque (≥4 mm in thickness, mobile, or ulcerative) identified in the ascending aorta or aortic arch by transthoracic/transesophageal echocardiography or coronary CT angiography.
-
Written informed consent provided by the participant or a legally authorized representative.
Exclusion Criteria:
- Presence of mechanical heart valves or rheumatic mitral stenosis.
- Requirement for antithrombotic agents other than apixaban and clopidogrel.
- Planned percutaneous coronary intervention, coronary artery bypass graft surgery, carotid endarterectomy, or intracranial stenting within 3 months after enrollment.
- Presence of mural thrombus in the heart confirmed by imaging.
- Renal impairment with creatinine clearance ≤25 mL/min.
- Severe hepatic impairment, including acute hepatitis, chronic active hepatitis, hepatic lesions or coagulopathy, hepatic failure, or laboratory evidence of AST/ALT >2× the upper limit of normal (ULN) or total bilirubin ≥1.5× ULN.
- Small-vessel occlusion (lacunar infarction) according to the TOAST classification.
- History within the past 30 days of gastrointestinal bleeding, vascular malformation of the brain or spinal cord, recent brain, spinal, or ophthalmologic surgery or trauma, esophageal varices, or intracranial hemorrhage at any time; or chronic regular use of NSAIDs (≥3 days per week for ≥2 consecutive weeks).
- Ischemic stroke occurring despite concurrent use of both NOAC and antiplatelet therapy.
- Planned surgery or high-bleeding-risk procedure within 3 months, or presence of active bleeding at enrollment.
- Anemia (hemoglobin < 8.0 g/dL) or thrombocytopenia (platelet count < 100,000/µL).
- Pre-stroke modified Rankin Scale (mRS) ≥ 2.
- Severe comorbid illness or malignancy not in complete remission with an expected life expectancy <1 year.
- Known hypersensitivity or allergy to apixaban or clopidogrel.
- Pregnant or breastfeeding women.
- Uncontrolled diabetes mellitus (HbA1c > 10.0%) or severe hypertension (systolic ≥ 220 mmHg or diastolic ≥ 120 mmHg).
- Concomitant use of strong CYP3A4 and P-glycoprotein inhibitors that can significantly increase apixaban exposure (e.g., ketoconazole, itraconazole, ritonavir, clarithromycin).
- Concomitant use of strong CYP2C19 inducers that can enhance clopidogrel antiplatelet effect and increase bleeding risk (e.g., rifampin, carbamazepine, phenytoin, phenobarbital, St. John's wort).
- Clinically significant mass effect due to space-occupying cerebral infarction, or patients expected to require decompressive craniectomy, including those with midline shift > 5 mm, loss of basal cisterns, herniation, fourth-ventricle compression, or obstructive hydrocephalus in posterior fossa infarcts.
- Intracranial hemorrhage or hemorrhagic transformation (PH1 or PH2) according to ECASS criteria.
- Participation in another interventional clinical trial within the past 30 days or concurrent participation in another interventional study (non-interventional observational or registry studies may be allowed at the investigator's discretion).
- Any other condition that, in the investigator's judgment, would make participation or continued involvement in the study inappropriate or infeasible.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Prevence
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Singl
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Apixaban and Clopidogrel Combination Therapy
Participants receive apixaban(5mg twice daily, or 2.5mg twice daily if indicated) plus clopidogrel 75mg daily for 30days, followed by apixaban monotherapy thereafter. |
Apixaban 5mg(or 2.5mg if indicated) twice daily. Used as monotherapy or in combination with clopidogrel for 30 days, then continued as monotherapy.
Ostatní jména:
Clopidogrel 75mg once daily for 30 days in combination with apixaban, then discontinued.
Ostatní jména:
|
|
Aktivní komparátor: Apixaban Monotherapy
Participants receive apixaban 5mg(or 2.5mg if indicated) twice daily as monotherapy for 30 days and continue apixaban monotherapy thereafter. |
Apixaban 5mg(or 2.5mg if indicated) twice daily. Used as monotherapy or in combination with clopidogrel for 30 days, then continued as monotherapy.
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Incidence of new symptomatic or asymptomatic ischemic lesions on DWI/FLAIR at 30(±5) days compared with baseline MRI, adjudicated by a central committee
Časové okno: At 30 ± 5 days after randomization
|
New ischemic lesions, either symptomatic or asymptomatic, identified on DWI/FLAIR at 30 (±5) days compared with baseline MRI, as adjudicated by a central adjudication committee. |
At 30 ± 5 days after randomization
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Incidence of symptomatic ischemic stroke or transient ischemic attack (TIA)
Časové okno: Within 90 days after randomization
|
Occurrence of new symptomatic ischemic stroke or transient ischemic attack confirmed by clinical and/or imaging criteria. |
Within 90 days after randomization
|
|
Incidence of acute coronary syndrome (ACS)
Časové okno: Within 90 days after randomization
|
Occurrence of acute coronary syndrome, including unstable angina or myocardial infarction, confirmed by standard diagnostic criteria. |
Within 90 days after randomization
|
|
Cardiovascular mortality
Časové okno: Within 90 days after randomization
|
Death due to fatal stroke, fatal myocardial infarction, or sudden death not clearly attributed to non-vascular causes. |
Within 90 days after randomization
|
|
Composite major cardiovascular events
Časové okno: Within 90 days after randomization
|
Composite of recurrent stroke (ischemic or hemorrhagic), acute coronary syndrome, or cardiovascular death. |
Within 90 days after randomization
|
|
All-cause mortality
Časové okno: Within 90 days after randomization
|
Death from any cause during the 90-day follow-up period. |
Within 90 days after randomization
|
|
Proportion of patients with modified Rankin Scale (mRS) score 0-2
Časové okno: At 90 days after randomization
|
Functional independence defined as mRS score of 0-2 at day 90. |
At 90 days after randomization
|
|
Proportion of patients with modified Rankin Scale (mRS) score 0-3
Časové okno: At 90 days after randomization
|
Favorable functional outcome defined as mRS score of 0-3 at day 90. |
At 90 days after randomization
|
|
Incidence of major bleeding events according to the ISTH criteria
Časové okno: Within 90 days after randomization
|
Major bleeding events defined by the International Society on Thrombosis and Haemostasis (ISTH) criteria, including fatal bleeding, symptomatic intracranial hemorrhage, intraocular bleeding causing vision loss, bleeding resulting in inability to perform usual activities, bleeding requiring transfusion of ≥2 units of whole blood or red cells, or bleeding leading to hospitalization. |
Within 90 days after randomization
|
|
Incidence of new asymptomatic cerebral hemorrhages detected on brain MRI(MR-Diffusion/FLAIR/SWI (or GRE))
Časové okno: At 30 ± 5 days after randomization
|
Newly developed asymptomatic cerebral hemorrhages identified on MR-Diffusion/FLAIR/SWI(or GRE) performed 30 ± 5 days after randomization. |
At 30 ± 5 days after randomization
|
Spolupracovníci a vyšetřovatelé
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Cerebrovaskulární poruchy
- Onemocnění mozku
- Onemocnění centrálního nervového systému
- Nemoci nervového systému
- Cévní onemocnění
- Kardiovaskulární choroby
- Patologické procesy
- Srdeční choroba
- Arytmie, srdeční
- Arteriální okluzivní onemocnění
- Intrakraniální arteriální onemocnění
- Patologické stavy, příznaky a symptomy
- Mrtvice
- Ischemie
- Fibrilace síní
- Arterioskleróza
- Intrakraniální arterioskleróza
- Sloučeniny síry
- Organické chemikálie
- Pyridiny
- Heterocyklické sloučeniny, 1 kruh
- Heterocyklické sloučeniny
- Heterocyklické sloučeniny, 2-prsten
- Heterocyklické sloučeniny, fúzované kroužek
- Thiofeny
- Ticlopidin
- Thienopyridiny
- Clopidogrel
- Apixaban
Další identifikační čísla studie
- 4-2025-0697
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .